Pittsburgh biotech firm involved in development of potential COVID-19 treatment

Nick Matoney

CHANDI: A PITTSBURGH COMPANY IS HELPING TO CREATE A DRUG TO FIGHT COVID-19. AND CLINICAL TRIALS COULD START IN THE NEAR FUTURE. THE BIOTECH COMPANY CYTOAGENTS, IS PARTNERING WITH A PHARMACEUTICAL COMPANY IN THE U.K. CALLED QUOTIENT. THE TWO COMPANIES HAVE JOINED FORCES TO WORK ON A LEAD COVID-19 DRUG CANDIDATE. FOR NOW, THE DRUG IS CALLED G.P.-1-6-8-1. THIS IS HOW IT WORKS. SCIENTISTS SAY WHEN A PERSON GETS SICK FROM VIRUSES, THEIR SYMPTOMS ARE TRIGGERED BY A CYTOKINE STORM. A CYTOKINE STORM IS AN EXCESSIVE IMMUNE RESPONSE THAT ATTACKS THE BODY AND MAKES COVID-19 PATIENTS FEEL SIC THE DRUG WOULD TARGET THE CAUSE OF LIFE THREATENING SYMPTOMS AND CONTROL THE BODY’S NATURAL IMMUNE RESPONSE. IN THE END, PATIENTS WHO CONTRACT THE VIRUS AND TAKE THE DRUG WOULD FEEL BETTER. THE COMPANY IS TRYING TO PREVENT THE NEED FOR VENTILATORS. >> IF SUCCESSFUL IT WILL CALM THIS CYTOKINE STORM AND REALLY ENABLE OUR BODY TO FIGHT THE VIRUS, BUT AT THE SAME TIME GET BETTER AND NOT PROGRESS INTO THIS ATTACKING OF YOUR BODY. CHANDI: THE CEO SAYS IF THIS DRUG DOES WELL, IT COULD HELP WITH OTHER RESPIRATORY DISEA

Pittsburgh biotech firm involved in development of potential COVID-19 treatment

Quotient Sciences and CytoAgents are working on way to treat COVID-19 Cytokine Storm

Updated: 12:11 PM EDT Apr 29, 2020

CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment.The treatment would focus on what is called a “cytokine storm,” which is an excessive immune response that attacks the body.The drug candidate being developed, GP1681, has been shown, according to a news release, to safely modulate the natural immune response by tamping down various cytokines.According to a news release, CytoAgents and Quotient will work together to develop and rapidly supply drug product for testing in certain phases this year and also focus on patient trials.There was no indication in the news release of when the process of seeking FDA approval for this treatment might get underway.

CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment.

The treatment would focus on what is called a “cytokine storm,” which is an excessive immune response that attacks the body.

The drug candidate being developed, GP1681, has been shown, according to a news release, to safely modulate the natural immune response by tamping down various cytokines.

According to a news release, CytoAgents and Quotient will work together to develop and rapidly supply drug product for testing in certain phases this year and also focus on patient trials.

There was no indication in the news release of when the process of seeking FDA approval for this treatment might get underway.


Source link

You May Also Like

About the Author: Nick Matoney

Leave a Reply

Your email address will not be published. Required fields are marked *

The maximum upload file size: 10 MB. You can upload: image, audio, video, document, spreadsheet, interactive, other. Links to YouTube, Facebook, Twitter and other services inserted in the comment text will be automatically embedded.